Skip to content

5-AminoLevulinic Acid as anti-sarcopenia Diet; study of efficacy and Dose dependency IN sarcopenia patients

5-AminoLevulinic Acid as anti-sarcopenia Diet; study of efficacy and Dose dependency IN sarcopenia patients - ALADDIN Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031200433
Enrollment
100
Registered
2021-03-22
Start date
2021-05-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenia

Interventions

Group A: administer 2 capsules of study food 1 (including ALA 50mg, SFC 29mg, and high zinc yeast 50mg per 2 capsules) per day (1 capsule at morning and 1 capsule at evening). Group B: administer 2 ca

Sponsors

Tamura Yoshifumi
Lead Sponsor
Watada Hirotaka
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male and female aged 65 years or older at giving their consent 2. male and female whose walking speed is less than 1m/sec, male whose grip power is less than 25kg, or female whose grip power is less than 20kg at giving their consent 3. Subjects whose BMI is less than 18.5 kg/m2, male whose lower leg circumference is less than 34cm, or female whose lower leg circumference is less than 33cm at giving their consent 4. male whose skeletal muscle index (SMI, kg/m2) measured by bioimpedance analysis (BIA) is less than 7.0kg/m2, or female whose SMI measured by BIA is less than 5.7kg/m2 at giving their consent 5. Subjects who provide their consent in a written form by themselves

Exclusion criteria

Exclusion criteria: 1. Subjects with rheumatism 2. Subjects with dementia 3. Subjects with severe renal dysfunction (whose eGFRcreat is less than 30mL/min/1.73m2) or subjects who are treated by dialysis 4. Subjects with severe hepatic dysfunction (whose AST or ALT is 3 times or more higher than the upper limit of normal at the study execution medical institution) 5. Crippled subjects who need legal representative for giving consent 6. Subjects with history of cerebral infarction or myocardial infarction 7. Subjects with pacemaker 8. Subjects with allergy against 5-aminolevulinic acid 9. Subjects with porphyria 10. Subjects with drug hypersensitivity, such as allergy against iron 11. Subjects with other conditions that the responsible investigator or subinvestigators think inappropriate to participate in the study

Design outcomes

Primary

MeasureTime frame
Change in skeletal muscle index (SMI, kg/m2) measured by bioimpedance analysis (BIA) from baseline to week 12

Secondary

MeasureTime frame
1. body weight 2. BMI 3. SMI (kg/m2) measured by BIA 4. basal metabolic rate 5. grip power 6. lower leg circumference 7. physical activity (METs) 8. 6m walking speed 9. Five-times-sit-to-stand test 10. SPPB (Short Physical Performance Battery) 11. SF-36 (MOS 36-Item Short-Form Health Survey) 12. BDI (Beck Depression Inventory) 13. EQ-5D (EuroQol 5 Dimension)

Contacts

Public ContactHideyoshi Kaga

Juntendo University Hospital

hkaga@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026